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Background: The impact of the drug-eluting stents (DES) on patients with chronic kidney disease (CKD) is not well evaluated, as these particular 
subsets of patients are consistently excluded from the randomized trials due to increasing mortality rate. In this prospective study, we assessed the 
clinical outcomes of the new generation DES implantation in patients with an isolated lesion in the proximal segment of the left anterior descending 
artery (pLAD) and CKD.
Methods: We enrolled 400 consecutive patients. Of these, 96 patients had CKD (estimated glomerular filtration rate <59 ml/min/1.73 m2) and 
304 without CKD (estimated glomerular filtration rate >60 ml/min/1.73 m2. The estimated glomerular filtration rate (eGFR) was calculated by using 
the Level Modification of Diet in Renal Disease (MDRD). Primary end points were major adverse cardiac events (MACE) and defined as: Death, non-
fatal myocardial infarction (MI) and target lesion revascularization (TLR). Stent thrombosis was also evaluated. Clinical or telephone follow-up was 
performed in both groups of patients.
Results: Angiographic characteristics were similar between the 2 groups. Demographic characteristics revealed a higher incidence of current 
smoking (p=0.002) and male gender (p=0.001) in patients with non-CKD, whereas patients with CKD were older (p=0.01) and hypertensive 
(p=0.02). Despite the fact that a significantly increased cardiac death rate was observed in CKD group (4.16% CKD group vs 0.65% non-CKD group, 
p=0.03), the overall MACE were similar between the 2 groups during the 18.01±9.15 follow-up period (p=0.19). The rate of non-fatal MI was 2.08% 
in the CKD arm vs 0.98% in the non-CKD arm (p=0.59). TLR rate was 2.08% in CKD group as compared with non-CKD group (2.96%), (p=0.99). The 
total thrombosis rate (definite/probable/possible) according to ARC definition was similar in both groups [6.25% CKD vs 2.63% non-CKD, (p=0.11)].
Conclusion: Although the TLR and the thrombosis rates are low in patients with CKD and pLAD lesion undergoing new generation DES implantation, 
the increased mortality rate is still a concern and should be further evaluated.
